The Impact of Continuous Transcutaneous CO2 (TCCO2) Monitoring in Extremely Low Birth Weight (ELBW) Infants
Overview
An observational study comparing outcomes of Extremely Low Birth Weight (ELBW) infants that were monitored with non-invasive Transcutaneous CO2 (TCCO2) monitor to infants that were not monitored by TCCO2 monitor.
Full Title of Study: “The Impact of Continuous Transcutaneous CO2 Monitoring (TCCO2) in Extremely Low Birth Weight (ELBW) Infants: A Prospective Observational, Multi-Center Study”
Study Type
- Study Type: Observational
- Study Design
- Time Perspective: Prospective
- Study Primary Completion Date: April 1, 2022
Arms, Groups and Cohorts
- Study group
- TCCO2 monitoring
- Control group
- Routine monitoring
Clinical Trial Outcome Measures
Primary Measures
- IVH-Intraventricular Hemorrhage
- Time Frame: Repeated scans until infant reaches corrected age of 42 weeks
- Intraventricular Hemorrhage
- PVL- Periventricular Leukomalacia
- Time Frame: Repeated scans until infant reaches corrected age of 42 weeks
- Periventricular Leukomalacia
Participating in This Clinical Trial
Inclusion Criteria
- ELBW infants Need of respiratory support Exclusion Criteria:
- Parental refusal IVH before study entry chromosomal abnormalities congenital central nervous system (CNS) abnormalities
Gender Eligibility: All
Minimum Age: 0 Minutes
Maximum Age: 24 Hours
Are Healthy Volunteers Accepted: No
Investigator Details
- Lead Sponsor
- Rambam Health Care Campus
- Provider of Information About this Clinical Study
- Principal Investigator: Liron Borenstein MD, Liron Borenstein Levin,MD, Neonatologist – Rambam Health Care Campus
Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.